Letter to the Editor
Clinical Pharmacology & Therapeutics (2005) 77, 587–588; doi: 10.1016/j.clpt.2005.02.011
Detection of CYP2C9*5 in a White Brazilian Subject*
Guilherme Suarez-Kurtz MD, DoctMed1, Rosane Vianna-Jorge PharmD, PhD1, Jamila A. Perini PharmD1 and Sergio D.J. Pena MD, PhD2
- 1Divisão de Farmacologia, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
- 2Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, GENE—Núcleo de Genética Médica, Belo Horizonte, Brazil
Correspondence: , E-mail: kurtz@inca.gov.br
*Research in the authors' laboratories is sponsored by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), and Swiss Bridge Foundation.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian PatientsClinical Pharmacology & Therapeutics Article Response
Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian PatientsClinical Pharmacology & Therapeutics Article Response
Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam *Clinical Pharmacology & Therapeutics Letter
CYP2C9 genotyping and phenotyping in Brazilians: effects on the pharmacokinetics of the NSAID tenoxicamClinical Pharmacology & Therapeutics null
*&showall=research" class="allmatches" target="_new">See all 6 matches for Research